AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

AbbVie announced the European commission approval of Maviret for treatment of patients with acute Hepatitis C in the EU. This follows approval in other geographies, and was an expected indication extension. Please find a link below to the official press release.

https://news.abbvie.com/2026-06-23-AbbVie-Announces-European-Commission-Approval-of-MAVIRET-R-Glecaprevir-Pibrentasvir-for-People-with-Acute-Hepatitis-C-Virus-Infection